ClinicalTrials.gg
CompletedNCT05970679Updated Aug 1, 2023

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

A Phase 3 interventional study of Ezetimibe/Atorvastatin 10/5 mg and Atorvastatin 5mg in Hypercholesterolemia, Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2022, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
32nd of 75
252 · median 148
Started
2022
the only one that year
Phase 3
31 of 77
none open now
Registered
75th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 32nd largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2022, is one of 31 in phase 3, and was the 75th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

A Randomized, Double blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient with primary Hypercholesterolemia or Mixed Dyslipidemia

03

Conditions studied

  • Hypercholesterolemia, Dyslipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both gender, the person aged 19 or older
  • Patients who are diagnosed with primary Hypercholesterolemia or Mixed Dyslipidemia
  • LDL- C ≤ 250 mg/dL and TG \< 500 mg/dL on fasting status

Exclusion criteria

Exclusion Criteria:

  • Patients with Myopathy, Rhabdomyolysis, Fibromyalgia, hereditary neuromuscular disorders or family history, or Creatine kinase(CK) ≥ 2 x (ULN) on Visit 1
  • Patients with severe renal disorders, Estimated Flomerular Filtration Rate () \< 30 mL/min/1.73m\^2 on Visit 1
  • Patients with hepatic failure or active or chronic hepatobiliary diseases or (AST) or alanine aminotransferase (ALT) ≥ 2.0 x ULN on visit 1
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    DW1125

    1 Ezetimibe/Atorvastatin 10/5 mg tablet orally once daily

    Drug: Ezetimibe/Atorvastatin 10/5 mg · Drug: DW1125A placebo · Drug: DW1125E placebo · Drug: DW1125A-1 placebo

  • Experimental
    DW1125A

    1 Atorvastatin 5 mg tablet orally once daily

    Drug: Atorvastatin 5mg · Drug: DW1125 placebo · Drug: DW1125E placebo · Drug: DW1125A-1 placebo

  • Placebo comparator
    DW1125E

    1 Ezetimibe 10mg tablet orally once daily

    Drug: Ezetimibe 10mg · Drug: DW1125 placebo · Drug: DW1125A placebo · Drug: DW1125A-1 placebo

  • Placebo comparator
    DW1125A-1

    1 Atorvastatin 10mg tablet orally once daily

    Drug: Atorvastatin 10mg · Drug: DW1125 placebo · Drug: DW1125A placebo · Drug: DW1125E placebo

Interventions

  • DrugEzetimibe/Atorvastatin 10/5 mg

    DW1125

  • DW1125A

  • DrugEzetimibe 10mg

    DW1125E

    Also known as: Ezetrol Tab. 10mg

  • DrugAtorvastatin 10mg

    DW1125A-1

    Also known as: Lipiwon Tab. 10mg

  • DrugDW1125 placebo

    Ezetimibe/Atorvastatin 10/5 mg placebo

  • DrugDW1125A placebo

    Atorvastatin 5mg placebo

  • DrugDW1125E placebo

    Ezetimibe 10mg placebo

  • DrugDW1125A-1 placebo

    Atorvastatin 10mg placebo

06

What researchers measure

Primary outcomes

  1. % Change of LDL-C

    % Change of LDL-C in week 8 from baseline

    Time frame: 8 weeks

Secondary outcomes

  1. % Change of LDL-C

    % Change of LDL-C in week 4 from baseline

    Time frame: 4 weeks

  2. % Change of Lipid parameters

    % Change of Lipid parameters(TC, TG, HDL-C, Non-HDL-C, Apo A1, Apo B) in week 4 and week 8 respectively after administrating the treatment drugs

    Time frame: 4 weeks and 8 weeks

  3. LDL-C goal achievement rates

    LDL-C goal achievement rates in week 4 and week 8 respectively after administrating the treatment drugs (goal achievement for LDL-C: low risk group: \< 160 mg/dL, intermediate risk group: \<130 mg/dL, high risk group: \< 100 mg/dL, extreme risk group: \< 70 mg/dL)

    Time frame: 4 weeks and 8 weeks

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2023, 7 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 1, 2023
StartActual
Aug 17, 2022
Primary completionActual
Apr 13, 2023
CompletionActual
Apr 13, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05970679
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 17, 2022
Primary completion
Apr 13, 2023
Completion
Apr 13, 2023
Last update
Aug 1, 2023

Study contacts

Kim
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion